Study wrapper · #1186
Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.
Editor's note
HFpEF has long resisted drug therapy, so a pooled 27 percent reduction in the composite of death or heart-failure hospitalization is a meaningful signal for the GLP-1 class — five of the six included studies used semaglutide, one tirzepatide. The effect is driven by hospitalizations rather than mortality, and 4,043 patients across six heterogeneous studies is still a modest evidence base. With zero statistical heterogeneity and low risk of bias in the RCTs, though, the direction of the finding looks solid.
Plain-language abstract
Pooling six studies with about 4,000 patients, this meta-analysis found that GLP-1 drugs — mostly semaglutide, plus one tirzepatide study — were linked to a 27 percent lower combined risk of death or heart-failure hospitalization in people with heart failure with preserved ejection fraction. The benefit came mainly from fewer hospitalizations; deaths alone did not fall significantly.